Suppr
超能文献

Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.

作者信息

Sharman J P, Chmielecki J, Morosini D, Palmer G A, Ross J S, Stephens P J, Stafl J, Miller V A, Ali S M

机构信息

Willamette Valley Cancer Institute, Eugene, OR.

Foundation Medicine Inc, Cambridge, MA.

出版信息

Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):e161-3. doi: 10.1016/j.clml.2014.06.004. Epub 2014 Jun 11.

DOI:10.1016/j.clml.2014.06.004

PMID:24997557

Abstract

摘要

相似文献

Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.

Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):e161-3. doi: 10.1016/j.clml.2014.06.004. Epub 2014 Jun 11.

Myeloma presenting during pregnancy.

Hematol Oncol. 2014 Mar;32(1):52-5. doi: 10.1002/hon.2088. Epub 2013 Sep 1.

Bortezomib in combination with thalidomide and dexamethasone--a successful treatment regimen in refractory extramedullary multiple myeloma.

Ann Hematol. 2008 Mar;87(3):253-4. doi: 10.1007/s00277-007-0401-8. Epub 2007 Oct 23.

Vemurafenib in pediatric patients with BRAFV600E mutated high-grade gliomas.

Pediatr Blood Cancer. 2014 Jun;61(6):1101-3. doi: 10.1002/pbc.24891. Epub 2013 Dec 3.

Bortezomib in combination with thalidomide-dexamethasone for previously untreated multiple myeloma.

Hematology. 2007 Jun;12(3):235-9. doi: 10.1080/10245330701214236.

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.

Lancet. 2010 Dec 18;376(9758):2075-85. doi: 10.1016/S0140-6736(10)61424-9. Epub 2010 Dec 9.

Mantle cell lymphoma arising in a multiple myeloma patient responding to lenalidomide.

Leuk Res. 2010 Jul;34(7):e178-80. doi: 10.1016/j.leukres.2010.01.002. Epub 2010 Jan 15.

Hodgkin's lymphoma as a second cancer in multiple myeloma never exposed to lenalidomide.

Ann Hematol. 2013 Jun;92(6):855-7. doi: 10.1007/s00277-012-1639-3. Epub 2012 Nov 25.

Spatially divergent clonal evolution in multiple myeloma: overcoming resistance to BRAF inhibition.

Blood. 2016 Apr 28;127(17):2155-7. doi: 10.1182/blood-2015-12-686782. Epub 2016 Feb 16.

Treatment of multiple myeloma: 2009 update.

Prescrire Int. 2009 Dec;18(104):263-6.

引用本文的文献

Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma.

Int J Mol Sci. 2023 Jan 31;24(3):2645. doi: 10.3390/ijms24032645.

A personalized molecular approach in multiple myeloma: the possible use of RAF/RAS/MEK/ERK and BCL-2 inhibitors.

Explor Target Antitumor Ther. 2022;3(4):463-479. doi: 10.37349/etat.2022.00095. Epub 2022 Aug 31.

RAS mutation leading to acquired resistance to dabrafenib and trametinib therapy in a multiple myeloma patient harboring BRAF mutation.

EJHaem. 2020 Aug 6;1(1):318-322. doi: 10.1002/jha2.8. eCollection 2020 Jul.

KRAS and RAS-MAPK Pathway Deregulation in Mature B Cell Lymphoproliferative Disorders.

Cancers (Basel). 2022 Jan 28;14(3):666. doi: 10.3390/cancers14030666.

Relapsed/Refractory Multiple Myeloma in 2020/2021 and Beyond.

Cancers (Basel). 2021 Oct 14;13(20):5154. doi: 10.3390/cancers13205154.

Pathway-Directed Therapy in Multiple Myeloma.

Cancers (Basel). 2021 Apr 1;13(7):1668. doi: 10.3390/cancers13071668.

Rapid Response in a Patient with Relapsed/Refractory Multiple Myeloma Treated with BRAF/MEK Inhibitors.

Case Rep Hematol. 2020 Dec 11;2020:8821415. doi: 10.1155/2020/8821415. eCollection 2020.

Combination of Dabrafenib and Trametinib for the Treatment of Relapsed and Refractory Multiple Myeloma Harboring BRAF V600E Mutation.

Case Rep Hematol. 2020 Oct 15;2020:8894031. doi: 10.1155/2020/8894031. eCollection 2020.

Vemurafenib in Patients With Relapsed Refractory Multiple Myeloma Harboring Mutations: A Cohort of the Histology-Independent VE-BASKET Study.

JCO Precis Oncol. 2018 Aug 31;2. doi: 10.1200/PO.18.00070. eCollection 2018.

Activating , , and mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma.

Proc Natl Acad Sci U S A. 2020 Aug 18;117(33):20004-20014. doi: 10.1073/pnas.2005052117. Epub 2020 Aug 3.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Suppr超能文献

Vemurafenib response in 2 patients with posttransplant refractory BRAF V600E-mutated multiple myeloma.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译